Abstract
The precise current role of fosfomycin in the management of uncomplicated UTI (uUTI) is not well defined in the published English literature (PubMed(™)). We aim to compare the overall curative efficacy, safety, and outcome of fosfomycin tromethamine vis-a-vis Ciprofloxacin therapy in the initial management of uncomplicated UTI in a select group of patients. After obtaining prior institutional ethical clearance and written informed consent, 120 consenting patients with uUTI were selected as per protocol (based on symptoms of uUTI, positive urine culture sensitivity (c/s), urine routine/microscopy (r/m) or positive urine leukocyte esterase dipstick (LED) test) and enrolled in this study. They were randomized by computer draw of lots, into two groups of 60 each, randomised to receive initial empirical therapy with either fosfomycin (F-intervention arm) or Ciprofloxacin (C-comparator arm), pending the urine culture report. Patients were followed up with urine culture analysis and other parameters. The primary outcome measures were clinical/bacteriological response/resolution of UTI documented by negative urine culture (sent on day 3), absence of pyuria, and negative urine LED on 3rd day. Urine c/s was sent at day 0, but treatment was started (based on randomization) for those with urine r/m positive and positive LED test, pending the result of c/s. If the urine c/s turned out to be negative, the patient was excluded from the study. For the patients who satisfied the inclusion criteria, urine c/s was again sent on day 3, based on which report, bacteriological cure was defined. Secondary outcomes included bacteriological spectrum, antimicrobial sensitivity pattern, incidence of UTI caused by extended spectrum beta-lactamase (ESBL) producing strains of Escherichia coli, possible risk factors for UTI, side effects, ADRs, and ADEs of the drugs. E. coli and Klebsiella were the commonest cause of UTI while ESBL uropathogens were detected in 14/120 (11.67% 11 and 3 in F/C groups, respectively) patients. The sensitivity of uropathogens to F and C was 86 and 50% respectively while the overall clinical curative efficacy (CCE) of same was 83 and 43% respectively. In the subset of 14 patients with UTI due to ESBL, the CCE of F and C was 91 and 67% respectively. Side effects (minor and self-limiting) were significantly more common with the F group (p < 0.001), with diarrhoea being the commonest. Hospitalization was the commonest risk factor for UTI (27%) though the association of risk factors with UTI was not significantly different (p = 0.609). Fosfomycin was safe and significantly more efficacious in treating uncomplicated UTI (p < 0.001) versus ciprofloxacin. The overall incidence of UTI due to ESBL strains was 12% in which the CCE of fosfomycin was significantly higher (p = 0.023).
Similar content being viewed by others
References
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG et al (2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52(5):103–120
Popovic M, Steinort D, Pillai S, Joukhadar C (2010) Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 29(2):127–142
Kahan FM, Kahan JS, Cassidy PJ, Kropp H The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci. 1974 May [cited 2017 Apr 12];235(1 Mode of Action):364–386. Available from: http://doi.wiley.com/10.1111/j.1749-6632.1974.tb43277.x
Patel S, Balfour J, Bryson H (1997) Fosfomycin tromethamine. Drugs 53(4):637–656 Available from: http://link.springer.com/10.2165/00003495-199753040-00007
The Clinical and Laboratory Standards Institute (2016) M100S performance Standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, Wayne
Warren JW (2001) Practice guidelines for the treatment of uncomplicated cystitis. Curr Urol Rep:326–329
Randrianirina F, Soares JL, Carod JF, Ratsima E, Thonnier V, Combe P et al (2007) Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Antananarivo, Madagascar. J Antimicrob Chemother 59(2):309–312
Nabeth P, Perrier-Gros-Claude JD, Juergens-Behr A, Dromigny JA (2005) In vitro susceptibility of quinolone-resistant Enterobacteriaceae uropathogens to fosfomycin trometamol, in Dakar, Senegal. Scand J Infect Dis 37(6–7):497–499
Hatzaki D, Poulakou G, Katsarolis I, Lambri N, Souli M, Deliolanis I et al (2012) Cefditoren: comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients. BMC Infect Dis 12(1):228 Available from: BMC Infectious Diseases
Ceran N, Mert D, Kocdogan FY, Erdem I, Adalati R, Ozyurek S et al (2010) A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections. J Infect Chemother 16(6):424–430
Muvunyi CM, Masaisa F, Bayingana C, Mutesa L, Musemakweri A, Muhirwa G et al (2011) Decreased susceptibility to commonly used antimicrobial agents in bacterial pathogens isolated from urinary tract infections in Rwanda: need for new antimicrobial guidelines. Am J Trop Med Hyg 84(6):923–928
Gupta K, Hooton TM, Stamm WE (2005) Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother 56(1):243–246
Aguinaga A, Gil-Setas A, Mazón Ramos A, Alvaro A, García-Irure JJ, Navascues A (2018) Uncomplicated urinary tract infections. Antimicrobial susceptibility study in Navarre. [article in Spanish]. An Sist Sanit Navar 41(1):17–26. https://doi.org/10.23938/ASSN.0125
Yang B, Yang F, Wang S, Wang Q, Liu Z, Feng W (2018) Analysis of the spectrum and antibiotic resistance of uropathogens in outpatients at a tertiary hospital. J Chemother 30(3):145–149. https://doi.org/10.1080/1120009X.2017.1418646
Alamri A, Hamid ME, Abid M, Alwahhabi AM, Alqahtani KM, Alqarni MS (2018) Trend analysis of bacterial uropathogens and their susceptibility pattern: a 4-year (2013-2016) study from Aseer region, Saudi Arabia. Urol Ann 10(1):41–46. https://doi.org/10.4103/UA.UA_68_17
Beierle I, Meibohm B, Derendorf H (1999) Gender differences in pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther 37(11):529–547
Schito GC (2003) Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 22(SUPPL. 2):79–83
Sire JM, Nabeth P, Perrier-Gros-Claude JD, Bahsoun I, Siby T, Macondo EA, Gaye-Diallo A, Guyomard S, Seck A, Breurec S, Garin B (2007) Antimicrobial resistance in outpatient Escherichia coli urinary isolates in Dakar, Senegal. J Infect Dev Ctries 1(3):263–268
Bozkurt O, Kara CAS (2008) Comparison efficacy of single dose fosfomycin with ciprofloxacin in the treatment of urinary tract infection in symptomatic women. Turk Urol Derg 34:360–362
Arslan H, Azap OK, Ergonul O, Timurkaynak F (2005) Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother 56(5):914–918
Akram M, Shahid M, Khan AU (2007) Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Ann Clin Microbiol Antimicrob 6(1):4 Available from: http://ann-clinmicrob.biomedcentral.com/articles/10.1186/1476-0711-6-4
Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N (2018) Effect of 5-day nitrofurantoin vs single-dose fosfomycin on clinical resolution of uncomplicated lower urinary tract infection in women: a randomized clinical trial. JAMA. 319(17):1781–1789. https://doi.org/10.1001/jama.2018.3627
Chervet D, Lortholary O, Zahar JR, Dufougeray A, Pilmis B, Partouche H (2018) Antimicrobial resistance in community-acquired urinary tract infections in Paris in 2015. Med Mal Infect 48(3):188–192. https://doi.org/10.1016/j.medmal.2017.09.013
Merino-Bohorquez V, Docobo-Pérez F, Sojo J, Morales I, Lupión C, Martín D (2018) Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2018.02.005
Kranz J, Schmidt S, Lebert C, Schneidewind L, Mandraka F, Kunze M (2018) The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients. Part II: therapy and prevention. Urol Int 100(3):271–278. https://doi.org/10.1159/000487645
Patel B, Patel K, Shetty A, Soman R, Rodrigues C (2017) Fosfomycin susceptibility in urinary tract Enterobacteriaceae. J Assoc Physicians India 65(9):14–16
Concia E, Bragantini D, Mazzaferri F (2017) Clinical evaluation of guidelines and therapeutic approaches in multi drug-resistant urinary tract infections. J Chemother 29(sup1):19–28. https://doi.org/10.1080/1120009X.2017.1380397
Bahramian A, Eslami G, Hashemi A, Tabibi A, Heidary M (2018) Emergence of fosfomycin resistance among isolates of Escherichia coli harboring extended-spectrum and AmpC β-lactamases. Acta Microbiol Immunol Hung 65(1):15–25. https://doi.org/10.1556/030.64.2017.030
Martín-Gutiérrez G, Docobo-Pérez F, Rodriguez-Beltrán J, Rodríguez-Martínez JM, Aznar J, Pascual A, Blázquez J (2017) Urinary tract conditions affect fosfomycin activity against Escherichia coli strains harboring chromosomal mutations involved in fosfomycin uptake. Antimicrob Agents Chemother 62(1). https://doi.org/10.1128/AAC.01899-17 Print 2018 Jan
Zykov IN, Samuelsen JL, Smabrekke L, Andersson DI, Sundsfjord A (2018) Pharmacokinetics and pharmacodynamics of fosfomycin and its activity against ESBL-, plasmid-mediated AmpC- and Carbapenemase-producing Escherichia coliin a murine urinary tract infection model. Antimicrob Agents Chemother 62. https://doi.org/10.1128/AAC.02560-17
Funding Statement
The authors certify that the above study was conducted entirely from within regular running expenditure available to the Government Institution and no extra institutional financial grant or funding was availed of in any manner whatsoever.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical Statement
The authors declare that the above manuscript is in compliance with Ethical Standards for research in human participants and have no potential sources of conflict of interest associated with its publication.
Conflict of Interest
The authors declare that they have no conflict of interest.
Informed Consent Statement
The authors also certify that informed consent was obtained from all the human participants in this study. The study protocol was registered with the Clinical Trials Registry of India (CTRI) bearing number CTRI/2017/09/009922.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Singh, I., Murtaza, S.M., Kaur, I.S. et al. Curative Efficacy of Fosfomycin Tromethamine Versus Ciprofloxacin in the Initial Therapy of Uncomplicated UTI—a Prospective Open-Label Randomised Controlled Clinical Study. Indian J Surg 82, 331–337 (2020). https://doi.org/10.1007/s12262-019-01947-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12262-019-01947-8